MétaCan
Menu
← Back to cohort
Record W4414314196 · doi:10.1093/ehjcvp/pvaf069

An old drug in a new era: digitoxin in the spotlight after DIGIT-HF

2025· article· en· W4414314196 on OpenAlexaff
Felice Gragnano, Mattía Galli, Paolo Calabrò, Dobromir Dobrev

Bibliographic record

VenueEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2025
Typearticle
Languageen
FieldPharmacology, Toxicology and Pharmaceutics
TopicChemical Reactions and Isotopes
Canadian institutionsUniversité de MontréalMontreal Heart Institute
Fundersnot available
KeywordsDrugDigitoxinDiabetes mellitusMEDLINEFeature (linguistics)

Abstract

fetched live from OpenAlex

For more than two centuries, cardiac (digitalis) glycosides have been used in the treatment of heart failure (HF), but robust randomized evidence has been limited. The landmark DIG trial,1 published in 1997, showed that digoxin had no effect on all-cause mortality (the primary outcome) but reduced hospitalizations for worsening HF (a secondary outcome), with benefits most evident at low serum concentrations. Of note, side effects and overdose risk with digoxin are well recognized and relatively frequent, particularly in elderly patients.1 Digitoxin, a related digitalis glycoside with high lipophilicity and mainly hepatic route of elimination, has long been viewed as a potential alternative, yet had never been rigorously tested in a contemporary randomized trial. Presented as a Hot Line trial at the European Society of Cardiology Congress 2025 in Madrid, the DIGIT-HF trial2 sought to fill this knowledge gap. In a Phase 4, double-blind, placebo-controlled study, 1240 patients with symptomatic HF and reduced left ventricular ejection fraction (LVEF) were randomized, of whom 1212 were included in the modified intention-to-treat analysis.2 Eligible patients had either an LVEF ≤ 40% and a New York Heart Association (NYHA) Class III-IV, or a LVEF ≤ 30% and a NYHA Class II. Background medications were consistent with guideline-directed medical therapy: over 90% received beta-blockers, 40% were on angiotensin receptor-neprilysin inhibitors, 76% on mineralocorticoid receptor antagonists, and nearly 20% on sodium-glucose cotransporter 2 inhibitors; implantable defibrillators and cardiac resynchronization therapy were reported in about 64% and 25%, respectively. Over a median follow-up of 36 months, the primary outcome of all-cause death or first hospitalization for worsening HF occurred in 39.5% of patients assigned to digitoxin and 44.1% of those receiving placebo [hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.69–0.98; P = 0.03]. All-cause mortality (HR 0.86; 95% CI 0.69–1.07) and first hospitalization for worsening HF (HR 0.85; 95% CI 0.69–1.05) were each numerically lower with digitoxin. Serious adverse events occurred slightly more often with digitoxin (4.7% vs. 2.8%). DIGIT-HF provides the first evidence from a randomized trial for a prognostic benefit of a cardiac glycoside on top of comprehensive guideline-directed medical and device therapy.2-5 Although the trial was underpowered relative to its original design, digitoxin appeared generally well tolerated with a simple titration protocol and may be particularly useful in patients with atrial fibrillation, higher heart rates, low blood pressure, or impaired renal function. DIGIT-HF marks a potential renaissance for cardiac glycosides in HF and is likely to inform future discussions on guideline recommendations and disease management. The data underlying this article were taken from the quoted references.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.059
GPT teacher head0.410
Teacher spread0.351 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart Journal - Cardiovascular Pharmacotherapy→Same topicChemical Reactions and Isotopes→French-language works237,207→